Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.8 USD | +2.04% | -15.08% | +62.16% |
05-10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
05-09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.16% | 1.63B | |
+29.11% | 49.18B | |
+0.95% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.29% | 26.09B | |
-22.68% | 18.71B | |
+8.11% | 13.26B | |
+32.04% | 12.32B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- JPMorgan Adjusts Price Target for Edgewise Therapeutics to $28 From $32, Maintains Overweight Rating